Homocysteine serum level and eye affection in Behҫet's disease patients

Document Type : Original Article

Authors

1 Rheumatology Department, Fayoum University, Fayoum, Egypt

2 Rheumatology Department, Beni Suef University, Beni Suef, Egypt

3 Ophthalmology Department, Beni Suef University, Beni Suef, Egypt

4 Clinical Pathology Department, Beni Suef University, Beni Suef, Egypt

Abstract

Background: Vascular endothelial dysfunction represents the major pathogenesis abnormalities in Behçet’s disease (BD). Homocysteine (Hcy), a non-protein-forming amino acid was proposed to be involved in the inflammatory process, and increasing homocysteine concentrations in ischemia may lead to leukocyte recruitment in the affected tissue.  Aim: to find out the possible relation between homocysteine (HCY) serum level and ocular involvement in Behçet’s disease (BD) patients. Methods: 30 BD patients as classified by the new International Behçet's Disease Criteria (25 males and 5 females with the age mean 33.83 ± 9.41years) and 20 healthy control subjects (age and sex matched) were included. The patients were divided into two groups: those with BD and eye involvement (n=24) and those without ocular involvement (n= 6).  Results:  The mean serum HCY values in BD patients were substantially greater than in healthy controls (37.87 ± 10.31 and 21.80 ± 5.47 mmol/L, respectively; P <0.001). HCY readings were higher in patients with eye involvement than in patients who did not have eye involvement. (38.91 ± 10.13 and 33.72 ± 10.9 mmol/L, respectively) yet, these differences did not reach the level of statistical significance (P>0.278). Conclusion: Serum HCY level is increased in BD. No association was found between HCY levels and eye involvement. Because hyperHCY is a treatable risk factor, measurement and monitoring of HCY levels may be a valuable index in the investigation, management and improving the outcome of patients with BD.

Keywords

Main Subjects

References

  1. Fouad NA, Ahmed TI., Shaker OG, Abdelaleemd OO:  Relation of ischemia-modified albumin to disease manifestations and activity in Egyptian patients with Behçet’s disease. Egypt Rheumatol Rehabil 2019; 46: 108–112. https://doi.org/10.4103/err.err_66_18 .
  2. Alpsoy E,      Leccese  p, Emmi G and   Ohno S: Treatment of Behçet's Disease: An Algorithmic Multidisciplinary Approach. MINI REVIEW article. Front. Med., 28 April 2021 | https://doi.org/10.3389/fmed.2021.624795.
  3. Alpsoy E, Bozca BC , Bilgic A: Behçet Disease: An Update for Dermatologists. Am J Clin Dermatol 2021;  22, 477–502 . https://doi.org/10.1007/s40257-021-00609-4.
  4.  Özyazgan Y and Bodaghi B : Eye Disease in Behçet’s Syndrome. In Yazıcı Y and Yazıcı H (eds) Behcet’s Syndrome. Springer New York Dordrecht Heidelberg London 2010; 5: 73-94.  
  5. Yücel  C ,    Omma   A,    Sertoğlu   E ,    Sezer   S ,    Turhan   T,    Özgürtaş    T :  Evaluation of atherogenic laboratory markers in Behçet’s disease patients with vascular involvement. Arch Med Sci 2020;16(3):531–537.  DOI: https://doi.org/10.5114/aoms.2018.79139
  6. Evereklioglu C, Er H, Tȕrköz Y, et al : Serum levels of TNF-α, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcet’s disease. Mediators of Inflammation 2002;11, 2: 87–93. doi: 10.1080/​09629350220131935
  7. Er H, Evereklioglu C, Cumurcu T,  et al : Serum homocysteine level is increased and correlated with endothelin-1 and nitric oxide in Behҫet’s disease. British Journal of Ophthalmology 2002; 86 (6): 653–657. DOI:10.1136/bjo.86.6.653
  8. Lee YJ, Kang SW, Yang JI, et al : Coagulation parameters and plasma total homocysteine levels in Behcet’s disease. Thrombosis Research 2002; 106: 1: 19–24. doi: 10.1016/s0049-3848(02)​00085-3.
  9. Upchurch GR Jr, Welch GN, Fabian AJ, et al : Homocysteine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997;272:17012–17017. This paper is available on line at http://www.jbc.org
  10. Bogdanski P, Pupek-Musialik D, Dytfeld J, et al : Plasma homocysteine is a determinant of tissue necrosis factor-α in hypertensive patients. Biomedicine and Pharmacotherapy 2008; 62 (6): 360–365. https://doi.org/10.1155/2008/407972 
  11. Yesilova Z, Pay S, Oktenli C, et al: (2005) Hyperhomocysteinemia in patients with Behҫet’s disease: is it due to inflammation or therapy?” Rheumatology International 2005; 25 (6): 423–428.  doi: 10.1007/​s00296-004-0466-9
  12. Davatchi F, Assaad-Khalil S, Calamia KT, et al : The International Criteria for Behcet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol 2014; 28(3): 338-47.  doi: 10.1111/jdv.12107.  
  13. Knapp RG, Miller MC. Clinical epidemiology and biostatistics. Published by Williams &​ Wilkins; Malvern, Pa. : Harwal Pub. Co., C.
  14. McHugh J :  Different phenotypes identified for Behçet syndrome. Nat Rev Rheumatol 2021; 17, 188 . https://doi.org/10.1038/s41584-021-00587-1
  15. Cansu DU, Kasifoglu T, Korkmaz C : Do clinical findings of Behcet's disease vary by gender?: A single-center experience from 329 patients. Europ J Rheumatol. 2016; ;3(4):157-60. [DOI:10.5152/eurjrheum.2016.038] 
  16. Davatchi F, Shahram F and Chams-Davatchi C :  Behcet’s disease: is there a gender influence on clinical manifestations? International Journal of Rheumatic Diseases 2012; 15(3): 306–314.   doi: 10.1111/j.1756-185X.2011.01696
  17. Aksu K, Turgan N, Oksel F , et al :  Hyperhomocysteinaemia in Behҫet’s disease. Rheumatology 2001; 40 (6): 687–690. https://doi.org/10.1093/rheumatology/40.6.687.
  18. Korkmaz C, Bozan B, Kosar M, et al :  Is there an association of plasma homocysteine levels with vascular involvement in patients with Behçet's syndrome? Clin Exp Rheumatol 2002; 20 (26):30-34. https://doi.org/10.1161/ATVBAHA.110.207068
  19. Houman H, Feki M, Ghorbel I B, et al :  Does hyperhomocysteinemia increase the risk of thrombosis in Behҫet’s disease?. Advances in Experimental Medicine and Biology 2003; 528, 413–417.  DOI:10.1155/2010/361387    https://doi.org/10.1007/978-1-4419-5641-5_5.
  20. Ates A, Aydintug O, Olmez U,  et al :  Serum homocysteine level is higher in Behçet’s disease with vascular involvement. Rheumatol Int 2005; 25(1):42–44. https://doi.org/10.1007/s00296-003-0398-9
  21. Sarican T, Ayabakan H, Turkmen S,  et al :  Homocysteine: an activity marker in Behҫet’s disease? Journal of Dermatological Science 2007; 45 (2): 121–126. DOI:10.1016/j.jdermsci.2006.11.008
  22. Elbay AE, Topalkara A, Elbay A, et al : Evaluation of Serum Homocysteine and Leptin Levels in Patients with Uveitis. Turk J Ophthalmol2015; 45: 146-151. doi: 10.4274/tjo.26539.
  23. Hamzaoui A, Chelbi H, Sassi FH and Hamzaoui K :  Release of B cell-activating factor of the TNF family in bronchoalveolar lavage from Behçet’s disease with pulmonary involvement. Oxid Med Cell Longev 2010;. 3:122–8. doi: 10.4161/oxim.3.2.11149.
  24. Aflaki E, Mehryar M, Nazarinia MA,  et al : The Relation between serum homocysteine level and eye involvement in Behçet’s disease. Arch Iranian Med 2008; 11 (6): 625 – 628. : https://www.researchgate.net/publication/23443584
  25. Allam A, Ammar H and Radwan A :  Serum homocysteine level and eye involvement in Egyptian patients with Behҫet’s disease. The Egyptian Rheumatologist 2014;  36, 29–34. http://dx.doi.org/10.1016/j.ejr.2013.09.002
  26. Ates A, Aydintug O, Olmez U , et al : Serum homocysteine level is higher in Behçet’s disease with vascular involvement. Rheumatol Int 2005; 25(1):42–44. https://doi.org/10.1007/s00296-003-0398-9

 

Egyptian Journal of Medical Research
Volume 3, Issue 2
April 2022
Pages 253-265

Files

Share

How to cite

Statistics